Key result
A TAPSE/sPAP ratio < 0.23 independently predicted a composite of long-term mortality and hospitalization in patients with pulmonary arterial hypertension (HR 10.928).
Why the study?
Risk stratification and RV function assessment are crucial in PAH, and TAPSE/sPAP has shown prognostic utility in various cardiac diseases.
Does TAPSE/sPAP predict long-term prognosis in patients with pulmonary arterial hypertension?
Cohort (n=41)
No
Does TAPSE/sPAP predict long-term prognosis in patients with pulmonary arterial hypertension?
The study aims to evaluate the utility of the echocardiographic parameter TAPSE/sPAP as a predictor of long-term prognosis in patients with pulmonary arterial hypertension.
TAPSE/sPAP may aid PAH risk stratification; leaves open whether it adds value beyond validated scores in prospective cohorts.
Introduction: Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease in which the risk stratification and the prognostic evaluation play a crucial role. Assessment of RV function is an important part of the follow-up. Tricuspid annular plane systolic excursion to systolic pulmonary artery pressure ratio (TAPSE/sPAP) is a simple, and readily available echocardiographic parameter which was stated as a prognostic predictor in various cardiac diseases. Herein, our aim was to evaluate the role of TAPSE/sPAP in prediction of long-term prognosis in PAH.
No takes yet. Share an insight, caveat, or question.
Uygur et al. (2021) conducted a cohort in Pulmonary arterial hypertension (n=41). TAPSE/sPAP < 0.23 vs. TAPSE/sPAP ≥ 0.23 was evaluated on Composite of mortality or hospitalization (HR 10.928, 95% CI 2.240-53.316, p=0.003). A TAPSE/sPAP ratio < 0.23 independently predicted a composite of long-term mortality and hospitalization in patients with pulmonary arterial hypertension (HR 10.928).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: